A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations.

Pingli WangLiming CaoPanwen TianShengxiang RenLiyun MiaoChengzhi ZhouYun FanYuping LiDongqing LvXin ZhaoMei YangChaonan ZhuBing YuJune XuYong SongKai Wang

Published in: Cancer communications (London, England) (2023)

Keyphrases

phase ii study
advanced non small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
open label
locally advanced
small cell lung cancer
placebo controlled
rectal cancer
squamous cell carcinoma
clinical trial
randomized controlled trial